U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949422) titled 'Application of 177Lu-SSTR2 Antagonist Therapy in Advanced Neuroendocrine Tumors' on Nov. 14.
Brief Summary: This single-center, prospective, single-arm exploratory study will evaluate the safety, feasibility, and preliminary effectiveness of lutetium-177 (177Lu)-labeled SSTR2 antagonist therapy in two patients with advanced gastroenteropancreatic neuroendocrine tumors. Eligible patients will have grade 1-2, somatostatin receptor-positive tumors that cannot be surgically removed or have spread, and have progressed despite somatostatin analogue therapy. Participants will receive 3-4 intravenous treatments, generally every 8 weeks, at ...